Companies / Germany
Teva, Mylan Compete For Merck KGaA's Generics Arm
May 2007 | Industry NewsThe race for the generics business of Germany's Merck KGaA looks to be heading into the final stages with two firms thought to be leading the bidding - Israel's Teva , and US-based Mylan. At the time of press, Teva appears to have the upper hand, due to its larger market cap, although company officials have been silent on the possibility of a deal. However, Mylan could still surprise with an aggressive offer.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
